MetLife Investment Management LLC Boosts Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

MetLife Investment Management LLC increased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 129.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,638 shares of the life sciences company’s stock after purchasing an additional 22,334 shares during the period. MetLife Investment Management LLC’s holdings in Integra LifeSciences were worth $720,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in IART. Blue Trust Inc. boosted its position in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares during the period. CWM LLC lifted its stake in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares during the last quarter. KBC Group NV boosted its holdings in Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after acquiring an additional 1,120 shares during the period. Canada Pension Plan Investment Board bought a new position in Integra LifeSciences during the 2nd quarter worth approximately $114,000. Finally, Northwest Investment Counselors LLC purchased a new position in Integra LifeSciences in the 3rd quarter worth approximately $73,000. Institutional investors own 84.78% of the company’s stock.

Insider Activity

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.10% of the company’s stock.

Integra LifeSciences Price Performance

IART stock opened at $24.10 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $45.42. The firm has a 50-day moving average of $21.44 and a 200 day moving average of $23.88. The company has a market cap of $1.86 billion, a P/E ratio of -267.75, a PEG ratio of 0.82 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the prior year, the company earned $0.76 EPS. The business’s revenue was down .4% compared to the same quarter last year. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Morgan Stanley started coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target on the stock. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Citigroup raised their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Finally, Bank of America lowered their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.